Sarah Sammons: I have always suspected our lobular patients did better with capecitabine!
Sarah Sammons, an oncologist at the Dana-Farber Breast Oncology Center and an Assistant Prof. at the Harvard Medical School, shared a Twitter post by Jason A. Mouabbi, Chair of Lobular Breast Cancer Alliance, adding the following:
“This is wonderful work. I have always suspected our lobular patients did better with capecitabine!”
Quoting Jason A. Mouabbi’s post:
“Exciting news from Oncology Journal following the impactful SABCS23! Our recent MD Anderson News publication addresses a pivotal question: In the era of ADC, where patients must have received ≥ 1 prior chemotherapy agent, should capecitabine or a taxane be utilized for ILC patients?
Our compelling findings strongly advocate for capecitabine’s superiority: 8.8 vs 5.0 months HR 0.63, P < .001.
Delving deeper, our multivariate analyses unveil key insights—favorable PFS and OS with fewer metastatic sites and increased lines of prior ET.
Notably, our study sheds light on racial disparities; Black patients face challenging OS outcomes compared to their White counterparts (HR 2.46; P = .001).
Explore the full details here.”
Source: Sarah Sammons/Twitter and Jason A. Mouabbi/Twitter
